- NCIt
- C132146
Loading cancer entity…
Loading cancer entity…
Clinical trials
900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (101)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04605614 | 64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Aug 12, 2026 | clinicaltrials |
| NCT07449481 | A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors | withdrawn | Phase 2 | 0 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 16, 2026 |
| NCT04500548 | Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 2 | Jun 10, 2026 | clinicaltrials |
| NCT05660421 | Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors | withdrawn | Phase 2 | 0 | Douglas JohnsonOTHER | 0 | Apr 27, 2026 | clinicaltrials |
| NCT06626256 | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Dec 24, 2025 | clinicaltrials |
| NCT04372641 | Testing the Safety of CB-5339 in Patients With Cancer | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2025 | clinicaltrials |
| NCT04557709 | Major Complication Rate in Cancer Patients With Neutropenic Fever Potentially Eligible for a Hospital at Home Program | withdrawn | — | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 4, 2025 | clinicaltrials |
| NCT06494046 | Defining Musical Toxicity and Its Effect on Patient Well-being | withdrawn | — | 0 | Mayo ClinicOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT04820894 | Perception of Cure Among Patients With Metastatic Cancer | withdrawn | — | 0 | City of Hope Medical CenterOTHER | 0 | May 23, 2025 | clinicaltrials |
| NCT05600556 | Virtual Reality for the Improvement of Patients Understanding of Disease and Treatment (MRgRT) | withdrawn | N/A | 0 | Thomas Jefferson UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06834386 | Suvorexant for Insomnia to Prevent Delirium in Hospitalized Cancer Patients | withdrawn | Phase 4 | 0 | Mayo ClinicOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT05653661 | Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors | withdrawn | Phase 1 | 0 | Mayo ClinicOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT05515692 | Electron Beam Radiotherapy for the Treatment of Refractory Sclerodermatous Chronic Graft Versus Host Disease | withdrawn | Early Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Jul 23, 2024 | clinicaltrials |
| NCT05403580 | Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer | withdrawn | Phase 3 | 0 | Mayo ClinicOTHER | 0 | May 6, 2024 | clinicaltrials |
| NCT06400264 | Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | May 6, 2024 | clinicaltrials |
| NCT05238831 | SMMART Adaptive Clinical Treatment (ACT) Trial | withdrawn | Early Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Jan 23, 2024 | clinicaltrials |
| NCT04870034 | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer | withdrawn | Early Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT05728372 | 64Cu-DOTA Pembrolizumab for Imaging Metastatic Solid Tumors in Patients Receiving Stereotactic Body Radiation | withdrawn | Early Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Oct 10, 2023 | clinicaltrials |
| NCT05169151 | Mobility and Physical Activity in Adolescent and Young Adult Cancer Patients or Survivors at Risk for Cardiovascular Morbidity and Frailty, The MOBILE AYA Study | withdrawn | — | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 24, 2023 | clinicaltrials |
| NCT05038384 | Palliative, Rehabilitation, and Integrated Medicine Handbook for Self Care at Work | withdrawn | — | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 31, 2023 | clinicaltrials |
| NCT05472220 | Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma | withdrawn | Phase 1 | 0 | Pamela MunsterOTHER | 0 | Dec 27, 2022 | clinicaltrials |
| NCT05010096 | BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 27, 2022 | clinicaltrials |
| NCT04803630 | Thermal Therapy for the Treatment of Depression in Cancer Survivors, the S-WARM Study | withdrawn | Early Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | May 12, 2022 | clinicaltrials |
| NCT03868423 | Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers | withdrawn | Phase 2 | 0 | Sameek RoychowdhuryOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT04498520 | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer | withdrawn | Phase 1 | 0 | Pamela MunsterOTHER | 0 | May 18, 2021 | clinicaltrials |
| NCT04455958 | Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year | withdrawn | Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Apr 26, 2021 | clinicaltrials |
| NCT03925428 | Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Sep 28, 2020 | clinicaltrials |
| NCT04439305 | Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X) | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 20, 2020 | clinicaltrials |
| NCT03217253 | Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2020 | clinicaltrials |
| NCT00997360 | Study of PKI-179 Administered Orally to Subjects With Solid Tumors | withdrawn | Phase 1 | 0 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 0 | Sep 27, 2018 | clinicaltrials |
| NCT03326258 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 18, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Aug 12, 2026source: clinicaltrials